The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
作者信息
Fox Christopher P, Chaganti Sridhar, McIlroy Graham, Barrington Sally F, Burton Cathy, Cwynarski Kate, Eyre Toby A, Illidge Timothy, Kalakonda Nagesh, Kuhnl Andrea, McKay Pam, Davies Andrew J
机构信息
School of Medicine, University of Nottingham, Nottingham, UK.
Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, UK.
出版信息
Br J Haematol. 2024 Apr;204(4):1178-1192. doi: 10.1111/bjh.19273. Epub 2024 Jan 21.
Abstract
摘要
相似文献
1
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.新诊断的大B细胞淋巴瘤的管理：英国血液学学会指南
Br J Haematol. 2024 Apr;204(4):1178-1192. doi: 10.1111/bjh.19273. Epub 2024 Jan 21.
2
New standards of care for treatment of diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤治疗的新标准。
Br J Haematol. 2024 Apr;204(4):1132-1134. doi: 10.1111/bjh.19295. Epub 2024 Jan 22.
3
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.经典型霍奇金淋巴瘤一线管理指南——英国血液学学会指南
Br J Haematol. 2022 Jun;197(5):558-572. doi: 10.1111/bjh.18083. Epub 2022 Feb 22.
4
The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper.弥漫性大B细胞淋巴瘤中枢神经系统复发的预防：英国血液学学会实用指南文件
Br J Haematol. 2020 Sep;190(5):708-714. doi: 10.1111/bjh.16866. Epub 2020 Jul 15.
5
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era.诊断时的单核细胞计数是弥漫性大 B 细胞淋巴瘤的预后参数：一项大型多中心研究的结果，该研究涉及利妥昔单抗治疗前后的 1191 例患者。
Haematologica. 2014 Jan;99(1):125-30. doi: 10.3324/haematol.2013.088161. Epub 2013 Aug 9.
6
Diagnosis and Management of Diffuse Large B-Cell Lymphoma: Society of Medical Oncology, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology Joint Clinical Practice Guideline.弥漫性大 B 细胞淋巴瘤的诊断与治疗：医学肿瘤学会、巴基斯坦血液病学会和巴基斯坦临床肿瘤学会联合临床实践指南。
JCO Glob Oncol. 2021 Sep;7:1647-1658. doi: 10.1200/GO.21.00320.
7
[Japanese Society of Hematology, clinical practice guideline: diffuse large B cell lymphoma].[日本血液学会，临床实践指南：弥漫性大B细胞淋巴瘤]
Rinsho Ketsueki. 2013 Oct;54(10):1756-63.
8
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.泊洛妥珠单抗联合免疫化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤患者的开放性、非随机、1b-2 期研究。
Lancet Oncol. 2019 Jul;20(7):998-1010. doi: 10.1016/S1470-2045(19)30091-9. Epub 2019 May 14.
9
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.泊洛妥珠单抗维达替尼治疗弥漫性大B细胞淋巴瘤患者的疗效评估。
Expert Rev Hematol. 2020 Sep;13(9):933-942. doi: 10.1080/17474086.2020.1795828. Epub 2020 Aug 10.
10
[Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].[新诊断的伴有弥漫性大B细胞淋巴瘤成分的滤泡性淋巴瘤的临床特征及预后]
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):456-462. doi: 10.3760/cma.j.issn.0253-2727.2022.06.003.
引用本文的文献
1
Ultrasonography-Guided Core-Needle Biopsy for Newly Diagnosed Large B-Cell Lymphomas: Analysis on Diagnostic Efficacy and Safety in an Italian Retrospective Study.超声引导下粗针活检用于新诊断的大B细胞淋巴瘤：一项意大利回顾性研究中的诊断效能与安全性分析
Acta Haematol. 2025 May 26:1-11. doi: 10.1159/000544794.
2
Incidence and risk factors of severe infections in diffuse large B-cell lymphoma patients undergoing immunochemotherapy.接受免疫化疗的弥漫性大B细胞淋巴瘤患者严重感染的发生率及危险因素
Ann Hematol. 2025 Apr 7. doi: 10.1007/s00277-025-06296-z.
3
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.4个周期后的中期正电子发射断层扫描（PET）可预测经组织分子学确诊的原发性纵隔B细胞淋巴瘤的预后。
Blood Adv. 2025 May 13;9(9):2232-2246. doi: 10.1182/bloodadvances.2024015577.
4
Uncommon presentation of diffuse large B-cell lymphoma: oral and pulmonary involvements in a young patient: a case report.弥漫性大 B 细胞淋巴瘤的不常见表现：年轻患者的口腔和肺部受累：一例报告。
J Med Case Rep. 2024 Oct 16;18(1):478. doi: 10.1186/s13256-024-04825-4.
本文引用的文献
1
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.在 REMoDL-B 研究中，对弥漫性大 B 细胞淋巴瘤患者进行了 5 年随访，根据分子亚群，与 R-CHOP 相比，硼替佐米的加入显示出不同的疗效。
J Clin Oncol. 2023 May 20;41(15):2718-2723. doi: 10.1200/JCO.23.00033. Epub 2023 Mar 27.
2
Management of secondary central nervous system lymphoma.继发性中枢神经系统淋巴瘤的管理
Br J Haematol. 2023 Jan;200(2):160-169. doi: 10.1111/bjh.18539. Epub 2022 Nov 21.
3
Patient initiated follow-up in cancer patients: A systematic review.癌症患者的患者自主随访：一项系统综述。
Front Oncol. 2022 Oct 13;12:954854. doi: 10.3389/fonc.2022.954854. eCollection 2022.
4
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.R-CEOP方案作为蒽环类药物不适用的弥漫性大B细胞淋巴瘤患者的一线治疗方案。
Blood Cancer J. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4.
5
Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey.淋巴结切除比核心活检能提供更准确的淋巴瘤诊断：法国淋巴病理网络调查。
Blood. 2022 Dec 15;140(24):2573-2583. doi: 10.1182/blood.2022015520.
6
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
7
Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors.与淋巴瘤共存或超越淋巴瘤：淋巴瘤幸存者未满足需求的快速综述。
Psychooncology. 2022 Jul;31(7):1076-1101. doi: 10.1002/pon.5973. Epub 2022 Jun 27.
8
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
9
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
10
Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities.对于患有弥漫性大B细胞淋巴瘤和心血管合并症的患者，R-CEOP方案的疗效较差。
Leuk Lymphoma. 2022 Mar;63(3):583-590. doi: 10.1080/10428194.2021.1992762. Epub 2021 Oct 21.
Zotero 插件